Serotonin-degradative pathways in the toad (Bufo bufo japonicus) brain: clues to the pharmacological analysis of human psychiatric disorders.

High levels of bufotenine (BUTN) and its precursor, N-methylserotonin, accumulate mainly in the brains of toads, particularly in the hindbrain regions. In a study involving urine samples from infant autistic patients, BUTN was detected, suggesting it could serve as a potential diagnostic marker for autism. The analysis utilized three-dimensional HPLC and indicates that these compounds may offer valuable insights into the neurological underpinnings of psychiatric conditions linked to serotonin methylation, highlighting a fascinating connection between toad biology and human mental health.

Study at a glance

Abstract

Bufotenine (BUTN) is a hallucinogen with psychotropic effects. High levels of BUTN and its precursor, N-methylserotonin are shown for the first time to occur and to accumulate mainly in the brain during the degradation of serotonin in the central nervous system of the toad, Bufo bufo japonicus. These compounds are concentrated in the hindbrain, which includes the cerebellum and medulla oblongata. BUTN can also be detected in blood and urine specimens from the toad. In humans, autism is a subtype of schizophrenia that appears to be a functional disease of the brain. BUTN can be detected in urine specimens from infant autistic patients. Analysis by three-dimensional HPLC suggests that the presence and levels of BUTN may be important markers for the diagnosis of autism. It appears, therefore, that some aspects of the central nervous system of Bufo may provide useful pharmacological clues to the etiology of human psychiatric diseases, such as autism, that are known to be linked to the methylation of serotonin.